Table 1.

Baseline and demographic characteristics of the study subjects.

	Study group (Growtropin-II) (n = 30)	Control group (Genotropin) (n = 30)	Non-treatment group (n = 15)	Total (n = 75)
Male/female	12/18	15/15	10/5	37/38
Chronological age (yr)	6.00 ± 0.99	5.47 ± 4.39	5.82 ± 8.56	5.75 ± 7.68
Bone age (yr)	4.56 ± 1.64	4.22 ± 1.12	5.13 ± 1.78	4.55 ± 1.51
Height (cm)	102.28 ± 21.43	99.71 ± .11	102.32 ± 2.45	101.26 ± 1.77
Height-SDS	−2.61 ± 0.79	−2.59 ± 0.63	−2.46 ± 0.64	−2.57 ± 0.69
Weight (kg)	15.75 ± .46	14.60 ± .77	15.65 ± .36	15.27 ± .64
BMI (kg/m2)	14.77 ± 1.33	14.58 ± 1.24	14.78 ± 1.35	14.70 ± 1.28
BMI-SDS	−1.00 ± 1.23	−1.05 ± 1.15	−0.97 ± 1.36	−1.01 ± 1.21
GA (wk)	38.07 ± .02	37.63 ± .63	37.53 ± .24	37.79 ± .12
Weight at birth (g)	2271.33 ± 760.20	2137.33 ± 371.71	2175.33 ± 717.23	2198.53 ± 993.44
Pretreatment height velocity (cm/yr)	5.50 ± 1.40	5.70 ± 2.04	5.43 ± 1.03	5.56 ± 1.61